Late Effects in Survivors of Acute Leukemia Treated with Hematopoietic Cell Transplantation: a Report from the Bone Marrow Transplant Survivor Study

K. Scott Baker, MD, MS1, Kirsten K. Ness, PhD2, Daniel Weisdorf, MD3, Liton Francisco4, Can-Lan Sun4, Stephen Forman, MD4, and Smita Bhatia, MD, MPH4

1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
2Department of Epidemiology & Cancer Control, St. Jude Children’s Research Hospital, Memphis, TN
3Department of Medicine, University of Minnesota, Minneapolis, MN
4Departments of Hematology and Hematopoietic Cell Transplantation and Population Sciences, City of Hope, Duarte, CA

Abstract

The Bone Marrow Transplant Survivor Study is a retrospective cohort study in which participants who received HCT between 1974–1998 and survived for ≥2 yr completed a 255 item questionnaire on late effects occurring after HCT. There were 281 survivors with AML and 120 with ALL. Siblings of participants (n=319) were recruited for comparison. Median age at interview was 36.5 yr for survivors and 44yr for siblings. Median follow-up after HCT was 8.4 yr. Conditioning included TBI in 86% of AML and 100% of ALL subjects. The frequencies of late effects did not differ between ALL and AML survivors. Compared to siblings, survivors had a higher frequency of diabetes, hypothyroidism, osteoporosis, exercise induced shortness of breath (EISB), neurosensory impairments, and problems with balance, tremor or weakness. In multivariable analysis, the risk of these outcomes did not differ by diagnosis. Survivors after allogeneic HCT had higher odds of diabetes (odds ratio [OR] 3.9, p=0.04), osteoporosis (OR 3.1, p=0.05), abnormal sense of touch (OR 2.6, p=0.02) and to report their overall health as fair or poor (OR 2.2, p=0.03). Ongoing surveillance for these late effects and appropriate interventions are required to improve the health status of ALL and AML survivors after HCT.

Keywords

survivorship; late effects; survivors; long term complications
Introduction

Acute leukemias (ALs: including acute lymphoblastic leukemia [ALL] and acute myeloid leukemia [AML]) are the most common indication for allogeneic hematopoietic cell transplantation (HCT) worldwide accounting for nearly 10,000 transplants reported worldwide to the Center for International Blood and Marrow Transplant Research (CIBMTR) in 2006. (1) HCT is routinely offered to patients with AL in second complete remission (CR), as well as to high-risk patients in first CR. Overall survival for patients who received matched-related HCT in first CR is reported to be 50–60%. (2, 3) Donor type (related vs. unrelated) does not appear to impact survival for patients receiving HCT in first CR. (4) Survival rates are lower after HCT in second CR, approaching 40%. Despite the fact that ALs account for the largest group of survivors after HCT, there have been few studies that have focused on the unique long-term outcomes and late-effects that these patients may face. The impact of HCT on organ function, functional performance, and quality of life (QoL) can be significant. We have previously investigated these outcomes in a population of patients who had undergone HCT for chronic myeloid leukemia (CML) and found that compared to age- and gender-matched siblings, CML survivors were more likely to develop ocular, oral, endocrine, gastrointestinal, musculoskeletal, and neurological impairments. (5) Presence of chronic graft vs. host disease (cGvHD) was the most important predictor of adverse medical late effects and also of poor overall health among CML survivors. On the other hand, patients who had undergone autologous HCT for lymphoma, reported a higher frequency of cataracts, dry mouth, hypothyroidism, osteoporosis, congestive heart failure, exercise induced shortness of breath, and neurosensory impairments as compared to the sibling comparison group. (6) These, and other issues that plague long-term survivors including the occurrence of new cancers (7–10) can increase the risk of premature death from non-relapse causes, (11, 12) and have been understudied in AL survivors. It is important to determine the burden of long-term morbidity after HCT for AL, so that patients may be appropriately counseled prior to HCT, and also so that targeted surveillance can be instituted for survivors.

Subjects and Methods

Participants

Eligible participants included individuals who received HCT at City of Hope (COH) or University of Minnesota (UMN) between 1974 and 1998 for AL; survived at least two years post-transplantation; were alive at study participation; and had completed the questionnaire in English. The Human Subjects Committee at the participating institutions approved the protocol; informed consent was provided according to the Declaration of Helsinki. Comparison with a non-cancer population was made possible by asking participating survivors to invite a nearest-age sibling to the study. A total of 319 siblings participated in this study.

Data collection

Clinical characteristics—Information regarding primary diagnosis, preparative regimens, stem cell source (autologous, sibling or unrelated donor), graft type (bone marrow
or peripheral blood stem cells), risk of relapse at HCT (standard- or high-risk), and prophylaxis and management of graft vs. host disease (GvHD), was obtained from institutional databases. Patients transplanted in first or second complete remission were considered at standard-risk for relapse; all others were considered at high-risk.

**Adverse events**—HCT survivors and siblings completed a 255-item BMTSS questionnaire, which covers the following general areas: questions regarding physical health conditions (endocrinopathies; central nervous system compromise; cardiopulmonary dysfunction; gastrointestinal and hepatic sequelae; musculoskeletal abnormalities; and subsequent malignancies) diagnosed by a healthcare provider, along with age at diagnosis; presence and severity of chronic GvHD; activity limitations that interfered with daily function; access to and use of medical care; and sociodemographic characteristics (race/ethnicity, education, marital status, employment, household income, and insurance). The reliability and validity of the BMTSS questionnaire has been tested, and the responses have demonstrated a high level of sensitivity and specificity, confirming that survivors are able to report the occurrence of adverse medical conditions with accuracy.\(^{13}\)

**Data analysis**

Descriptive statistics, including means, standard deviations, medians, ranges, frequencies and percents were calculated for demographic and treatment factors among HCT survivors, overall and stratified by diagnosis, and for the sibling comparison group. Demographic information was compared between survivors and the sibling comparison group with two sample t-tests and Chi-squared statistics. The frequencies of yes responses to the questions regarding organ system impairments, activity limitations, and health status were tabulated, again overall, stratified by diagnosis, and for the sibling comparison group. Proportions were compared on these outcomes between survivors and siblings with generalized estimating equations to allow for correlations between siblings and survivors in the same families. Models were adjusted for age and gender. To estimate the total burden of disease, the number of organ system impairments was summed for each participant and compared between survivors and siblings with a Wilcoxon rank sum test. The associations between diagnosis and treatment and organ system impairments and activity limitations were evaluated in multivariate logistic regression models, adjusting for age at transplant, age at interview and gender. Results are reported as odds ratios with 95% confidence intervals both for the overall HCT cohort and separately for those who received an allogeneic transplant. The presence of cGvHD was included in the predictive models for those who had an allogeneic transplant. SAS version 9.1 (Cary, NC) was used for all analysis.

**Results**

**Study participants**

Of the 673 eligible HCT survivors, 584 (87%) were successfully contacted, and 401 (69%) participated. Participants were more likely to be female (46.5% vs. 35.7%, p <0.001), older at HCT (26.3±14.4 years vs. 20.4±13.6 years, p<0.001) and at study participation (35.9±14.2 years vs. 31.7±13.5 years, p<0.001), when compared with non-participants. Finally, when compared with non-participants, there was an overrepresentation of AML.

Leukemia. Author manuscript; available in PMC 2011 June 01.
survivors among participants (70.1% vs. 57.4%, P < 0.001). Participants did not differ from non-participants by race/ethnicity, time since transplantation, treating institution, stem cell source or myeloablative regimen.

The clinical and demographic characteristics of the HCT survivors and their siblings are summarized in Table 1. When compared with the siblings, there was an overrepresentation of males and non-whites among the HCT survivors. Furthermore, HCT survivors were younger (median age at study participation: 36.5 years, when compared with the siblings were (median age: 44 years). AML was the predominant diagnosis group in this cohort of HCT survivors (70%). While over half of the AML survivors were female, two-thirds of the ALL survivors were male. Sixty percent of the survivors had a sibling donor and 83% had bone marrow as their primary donor source. The vast majority of HCT survivors (ALL: 100%. AML: 86%) received total body irradiation (TBI) as part of their conditioning regimen. The median length of follow-up was 8.4 (range 2.0–24.6) years. cGvHD was reported by 47% of AML survivors and 39% of ALL survivors in this cohort.

Comparison between HCT Survivors and Siblings

**Organ system impairment**—The age- and gender-adjusted comparison of the prevalence of organ system impairment among HCT survivors and siblings is summarized in Table 2. The comparison is presented between siblings and all AL survivors, as well as between siblings and ALL or AML survivors.

Overall, the prevalence of organ system impairments was higher among HCT survivors when compared with the siblings in nearly all systems examined.

**Ocular Impairment:** Ocular impairments including cataracts, glaucoma and dry eyes were reported by 44.6% of HCT survivors and 11.3% of siblings (p<0.001). The most common ocular impairment among survivors was cataracts (36.4%).

**Oral health:** Oral health problems, including dry mouth, swollen or bleeding gums, and problems chewing or swallowing were reported by 22.4% of the HCT survivors, and 12.9% of siblings (p=0.002). The most common oral health problem reported by the study participants was swollen and bleeding gums.

**Endocrine:** Endocrine dysfunction under consideration included thyroid disorders and diabetes, and were significantly more common in HCT survivors (29.4%), compared to siblings (11.3%, p<0.001). Hypothyroidism was the most common condition, reported by 23.2% of HCT survivors. Diabetes was reported significantly more commonly by HCT survivors (9%) compared to 3.1% of siblings (P<0.001).

**Bone health:** Osteoporosis and avascular necrosis were the two most commonly reported bone health issues, and were reported more frequently by HCT survivors compared to siblings (13.2% vs. 2.5%, p<0.001).

**Cardiopulmonary compromise:** Cardiopulmonary complications included coronary artery disease, congestive heart failure, arrhythmia, hypertension, valvular disorders, pericarditis,
pulmonary fibrosis, blood clots, and exercise-induced shortness of breath. The prevalence of cardiopulmonary compromise was comparable between HCT survivors and siblings, with the exception of exercise induced shortness of breath which was more common in survivors with a previous diagnosis of ALL (13.3%) than in either siblings (2.5%) or in HCT survivors with a previous diagnosis of AML (6.0%).

**Gastrointestinal complications:** Gastrointestinal problems included gallstones, hepatitis, cirrhosis, and esophageal strictures, and were reported by 16% of HCT survivors and 9% of siblings (p=0.002). Gallstones and hepatitis were the most frequently reported conditions.

**Neurological impairment:** Neurosensory and neuromotor impairments were reported more frequently by HCT survivors than the siblings. Abnormal sense of taste, smell, or touch as well as problems with balance, tremor or weakness constituted the most commonly reported neurological concerns.

**Total number of organ system impairments:** Thirty four percent of survivors and 42.9% of siblings reported no chronic conditions. Over one-third (38.2%) of HCT survivors reported impairments in more than one and 24% in more than two organ systems. Conversely, only 24.1% of siblings reported impairments in more than one and 8.7% in more than two organ systems (p < 0.001). The most frequent combination of multiple system involvement for both HCT survivors and siblings was oral health problems and cardiopulmonary compromise (2.0 and 2.5% respectively).

**Functional Status**—Limitations in functional status were assessed in the following domains: assistance with activities of daily living such as grooming, bathing or dressing, and assistance with routine activities like housework or shopping. Study participants were also asked whether health prevented work or school attendance. Finally, participants were asked to rate their health into one of the following categories: poor, fair, good, very good, and excellent. The majority of survivors did not report any limitations in functional status, however, for those who did, they were more likely than siblings to report the need for assistance with activities of daily living (3% vs. 0.3%, p=0.01), as well as the need for assistance with routine activities (7.7% vs. 2.5%, P=0.004, Table 3). Health problems interfered with school or work attendance in nearly 14% or survivors, but in only 2% of siblings (p<0.001). The majority of siblings and 82.9% of survivors rated their general health as good, very good, or excellent, although HCT survivors were more likely than siblings to report their health as fair or poor (16.7% vs. 5.3%, p<0.001).

**HCT Survivors: Clinical and demographic predictors of organ system and functional status compromise**

The results of the multivariate models evaluating the associations between demographic, clinical factors and select organ system impairments or functional status compromise are shown in Tables 4, 5 and 6. Table 4 includes outcomes for all survivors, while Table 5 is limited to those who received an allogeneic HCT. Table 6 provides data on functional status outcomes for all HCT recipients as well as that restricted to allogeneic HCT recipients. Data in all tables are adjusted for age at study participation and age at transplantation.
Cataracts—TBI-based conditioning was the only risk factor associated with an increased risk of cataracts among all HCT recipients (all HCT survivors: OR=4.58, 95% CI, 1.6–12.8, p=0.004; allogeneic HCT survivors: OR=5.33, 95% CI, 1.4–19.7, p=0.01).

Dry eyes—Allogeneic HCT recipients were at a 3.8-fold increased risk of reporting dry eyes when compared with autologous HCT recipients (OR=3.79, 95% CI, 1.7–8.6, p=0.001). Among allogeneic HCT recipients, patients with cGvHD were at a 3.3-fold increased risk of reporting dry eyes, when compared with those without cGvHD (OR=3.26, 95% CI, 1.7–5.4, p<0.001).

Dry mouth—Among allogeneic HCT recipients, presence of cGvHD was associated with a 2.4-fold increased risk of reporting dry mouth (OR=2.36, 95% CI, 1.0–5.4, p=0.04).

Diabetes—Allogeneic HCT recipients were at a 3.9-fold increased risk of reporting diabetes, when compared with autologous HCT recipients (OR=3.92, 95% CI, 1.1–14.0, p=0.04).

Osteoporosis—Factors associated with an increased risk of osteoporosis included allogeneic HCT (OR=3.1, 95% CI, 1.0–9.4, p=0.05) and female sex (OR=3.25, 95% CI, 1.4–7.4, p=0.005).

Avascular necrosis—Allogeneic HCT recipients were at a 5.4-fold increased risk of developing avascular necrosis, when compared with autologous HCT recipients (OR=5.38, 95% CI, 1.2–25.0, p=0.03).

Exercise-induced shortness of breath—Among allogeneic HCT recipients, patients who had received non-TBI based conditioning (OR=5.9, p=0.05) and those who had developed cGvHD (OR=3.4, 95% CI, 1.1–10.2, p=0.03) were at an increased risk of reporting exercise-induced shortness of breath.

Abnormal sense of touch—Overall, allogeneic HCT recipients were at a 2.6-fold increased risk of reporting abnormal sense of touch (OR=2.55, 95% CI, 1.2–5.5, p=0.02), when compared with autologous HCT recipients. Among allogeneic HCT recipients, those with cGvHD were 2.3-fold more likely to report an abnormal sense of touch (OR=2.26, 95% CI, 1.2–4.7, p=0.03).

Neurological impairment (balance, tremor, weakness)—Females were 2.4-fold more likely to report neurological impairment, as compared with males (overall: OR=2.43, 95% CI, 1.3–4.7, p=0.008; allogeneic HCT recipients: OR=3.73, 95% CI, 1.7–8.4, p=0.002). Among allogeneic HCT recipients, those with cGvHD were 2.6-fold more likely to report neurological problems (OR=2.64, 95% CI, 1.1–6.4, =0.02)

Health prevents school or work attendance—Among allogeneic HCT recipients, those with cGVHD were 2.9-fold more likely to report poor health impacting school or work attendance (OR=2.93, 95% CI, 1.3–6.4, p=0.008).
Self-reported poor/fair health—Allogeneic HCT recipients were 2.2-fold more likely to report their health as poor or fair, as compared with autologous HCT recipients (OR=2.15, 95% CI, 1.1–4.2, p=0.03). Survivors with a history of cGVHD were more than twice as likely to report abnormal sense of touch (OR 2.3, 95% CI 1.2–4.7, p=0.03), problems with balance, tremor or weakness (OR 2.6, 95% CI 1.1–6.1, p=0.02), and they were nearly three times more likely to report that their health prevented school or work attendance (OR 2.9, 95% CI 1.3–6.4, p=0.008). Despite these outcomes they were no more likely than survivors without cGVHD to report their health as being poor or fair.

Discussion

This report is the first to describe medical late effects and functional status in a large population of AL patients treated with HCT. We found that HCT survivors are at a significantly higher risk of developing chronic health conditions such as cataracts, oral health issues, hypothyroidism, diabetes, bone health abnormalities, gastrointestinal and neurological impairments, when compared with a healthy comparison group (although the differences in the prevalence of reported outcomes is large for some and small for others). Compared with their siblings, a minority of HCT survivors also reported the need for assistance with activities of daily living, other routine activities, or that their poor health prevented them from working or attending school which resulted in an overall poor rating of their health. However, despite these medical late effects and functional limitations, over 80% of the HCT survivors rated their overall health as good, very good, or excellent. Not surprisingly, recipients of allogeneic transplants and especially those who had cGVHD, were more likely to report adverse health conditions, functional impairments, and to rate their overall health as fair or poor. This analysis does not account for the comparative severity of different impairments that survivors face (i.e. diabetes may be considered a more severe impairment than dry mouth for example). However, we have shown that survivors face an overall greater burden of impairments with two-thirds of survivors facing impairments in two or more organ systems.

Overall, primary diagnosis of ALL or AML had little impact on the risk of specific long-term complications, functional or health status after HCT. Since management of ALL necessitates use of steroids, one might have expected a higher risk of outcomes such as diabetes, osteoporosis and avascular necrosis, but that was not the case. Our cohort includes individuals who had survived at least two years after HCT, and it is possible that events such as avascular necrosis may have occurred earlier post-HCT in patients who died before entering our cohort and thus were not captured in this study. Furthermore, we were not able to capture steroid exposure after HCT in this study, but we did not find that the risk of these outcomes was increased among patients who had cGVHD (and thus likely steroid exposure) than in those who did not have cGVHD.

We examined the impact of the preparative regimen, particularly TBI exposure, which has been reported to be associated with several long-term complications including hypothyroidism(14–16), cataracts(16–18), second cancers(7, 8, 19), and diabetes(20, 21). We found several similar associations here, although interestingly did not find a higher risk of hypothyroidism associated with TBI in this cohort. We also did not find that TBI was
related to long-term pulmonary complications such as exercise induced shortness of breath. In fact, this was reported less frequently in patients who had received TBI. While we do not report the details of the non-TBI based conditioning regimens, the majority of these patients received busulfan based regimens. Busulfan is known to have the potential to lead to long term pulmonary toxicities and pulmonary fibrosis(22), but the occurrence of fibrosis in HCT recipients independent of cGvHD is uncommon, and typically has not been reported more frequently in busulfan vs. TBI based preparative regimens(23, 24). We have previously reported the association of TBI with the development of diabetes(20), however, in this analysis we were not able to demonstrate this association as the number of events was too small to make reliable risk estimates.. Diabetes was, however, reported more commonly among survivors than among siblings.

This analysis reveals that allogeneic HCT recipients fare worse than the autologous HCT recipients, and have a higher risk of developing dry eyes, diabetes, osteoporosis, avascular necrosis, abnormal sense of touch and poorer overall health. In the analysis restricted to allogeneic HCT recipients the only significant risk factor for several of these outcomes was cGVHD, which also had an impact on the survivors' health status and made them less likely to be able to attend school or work. Autologous HCT recipients are not at risk for cGVHD, and therefore do not carry the risk of adverse events that are typically associated with cGVHD.

In a previous study, we have demonstrated that cGVHD has a significant impact on general health, mental health, functional status, activities of daily living, and pain in HCT survivors. (25) In this current study cGVHD remains one of the primary risk factors for the development of chronic health conditions or activity limitations in leukemia survivors after allogeneic HCT. However, allogeneic HCT survivors with a history of cGVHD were not any more likely to report their overall health as fair or poor compared to allogeneic survivors who did not have cGVHD. This finding is similar to what we have reported previously where only a history of having had cGVHD in itself did not have a negative impact on overall health status if the cGVHD was considered resolved.(25) While management options for cGVHD have improved, the increasing use of mismatched and unrelated donors, peripheral blood stem cell grafts, and donor lymphocyte infusions have prevented a decline in its incidence, thus aggressive surveillance and multidisciplinary management of secondary complications in patients with cGVHD is critical.

One of the purposes of a disease focused analysis of long term complications after HCT such as this is to determine whether there are unique aspects of the underlying disease or type of treatment received prior to HCT that might impact the long term outcomes after HCT. While we are not able to account for pre-transplant treatment factors in this analysis, there are not significant differences in the types of post-transplant late effects discovered in this analysis as compared to what has been reported for survivors after HCT for CML(5), or for survivors after HCT for lymphoma(6). In addition, despite exposure to anthracyclines in the majority of acute leukemia patients, we did not find an increased risk of cardiopulmonary impairments overall, or for congestive heart failure in particular, in HCT survivors compared to sibling controls. The subjects in all three of these studies however were mostly adults. It is possible that in a pediatric population there may be a greater impact
of pre-HCT treatments on subsequent post-HCT late effects. Additionally, differences may begin to appear with longer follow-up of these cohorts.

There are limitations to this study that must be considered when interpreting the findings. The data are collected by self-report and subject to potential misclassification bias where subjects may either incorrectly report conditions that they did not have, or fail to report conditions that they did have. However, a validation study of the BMTSS instrument demonstrated very good agreement between self-report conditions and those abstracted from medical records. Additionally, the control group (siblings) also provided self-reported data thus there should not be any systematic bias based on case or sibling status. Participation rate was 59.6% of those presumed eligible and 69% of those successfully contacted which could introduce some bias if the prevalence of outcomes among study participants differed significantly from that of non-participants. We know that participants did not differ from non-participants by time since transplant, treating institution, stem cell source or myeloablative regimen. However, as is true for most large HCT cohort studies, participants were more likely to be female, to have a diagnosis of AML and to be slightly older than non-participants at time of HCT and at time of study participation. Finally, participants in this study had to be alive at least 2 years after HCT to be eligible for study participation, and thus there may be an underestimation for some outcomes that might have occurred in patients who died within the first 2 years after HCT.

A final issue is whether these results are relevant in the current era of HCT since patients in this study received their transplants over 10 years ago. For patients with acute leukemia, the most common myeloablative preparative regimens in use (busulfan/ cyclophosphamide or TBI/ cyclophosphamide) have not changed significantly over the past three decades. In addition, while HLA matching methods have improved, the incidence of cGvHD in this cohort (40–45%) is not significantly different that what is seen currently, thus we feel the data maintain their relevance even in the context of patients receiving HCT currently.

In summary, this study provides disease-specific data on long term outcomes in a large cohort of survivors after HCT for acute leukemia. Many of the impairments which have been identified are potentially amenable to interventions targeted towards either prevention or amelioration of the negative impact on the survivors' overall health and well being. We have also shown that at one end of the spectrum, one-third of survivors report no long-term impairments, while at the other end the other third report having multiple impairments. Therefore we have identified that there is a subset of survivors for which we should be focusing additional efforts towards support and intervention. The data also indicate that appropriate education of healthcare providers regarding issues facing HCT survivors, as well as education of survivors themselves, will be required for maintaining their long-term health.

Acknowledgements

This study was supported in part by grants from the National Institute of Health (R01 CA078938 [S.B.], P01 CA 30206 [S.J.F.], K23 CA85503-01 [K.S.B.]), and the Leukemia Lymphoma Society (2192) (S.B.).
References

1. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: Part I - CIBMTR Summary Slides, 2009. CIBMTR Newsletter. 2009:7–11. serial online.

2. Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P, et al. The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Children: An Evidence-Based Review. Biology Blood and Marrow Transplantation. 2005; 11(11): 823–61.

3. Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P, et al. The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Adults: An Evidence-based Review. Biology Blood and Marrow Transplantation. 2006; 12(1):1–30.

4. Kiehl MG, Kraut L, Schwerdtfeger R, Hertenstein B, Remberger M, Kroeger N, et al. Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation in Adult Patients With Acute Lymphoblastic Leukemia: No Difference in Related Compared With Unrelated Transplant in First Complete Remission. J Clin Oncol. Jul 15; 2004 22(14):2816–25. 2004. [PubMed: 15254049]

5. Baker KS, Gurney JG, Ness KK, Bhatia R, Forman SJ, Francisco L, et al. Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. Blood. Sep; 2004 104(6):1898–906. [PubMed: 15172972]

6. Majhail NS, Ness KK, Burns LJ, Sun CL, Carter A, Francisco L, et al. Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study. Biol Blood Marrow Transplant. Oct; 2007 13(10):1153–9. [PubMed: 17889351]

7. Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol. Apr 1; 2003 21(7):1352–8. [PubMed: 12663726]

8. Bhatia S, Ramsay NK, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ, et al. Malignant neoplasms following bone marrow transplantation. Blood. May 1; 1996 87(9):3633–9. [PubMed: 8611687]

9. Kolb HJ, Socie G, Duell T, Van Lint MT, Tichelli A, Apperley JF, et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med. Nov 16; 1999 131(10):738–44. [PubMed: 10577296]

10. Socie G, Curtis RE, Deeg HJ, Sobocinski KA, Filipovich AH, Travis LB, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol. Jan; 2000 18(2):348–57. [PubMed: 10637249]

11. Bhatia S, Francisco L, Carter A, Sun CL, Baker KS, Gurney JG, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. Nov 15; 2007 110(10):3784–92. [PubMed: 17671231]

12. Bhatia S, Robison LL, Francisco L, Carter A, Liu Y, Grant M, et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood. Jun; 2005 105(11):4215–22. [PubMed: 15701723]

13. Louie AD, Robison LL, Bogue M, Hyde S, Forman SJ, Bhatia S. Validation of self-reported complications by bone marrow transplantation survivors. Bone Marrow Transplant. Jan; 2000 25(11):1191–6. [PubMed: 10849532]

14. Berger C, Le-Gallo B, Donadieu J, Richard O, Devergie A, Galambrun C, et al. Late thyroid toxicity in 153 long-term survivors of allogeneic bone marrow transplantation for acute lymphoblastic leukaemia. Bone Marrow Transplant. May; 2005 35(10):991–5. [PubMed: 15806126]

15. Faraci M, Barra S, Cohen A, Lanino E, Grisolia F, Miano M, et al. Very late nonfatal consequences of fractionated TBI in children undergoing bone marrow transplant. Int J Radiat Oncol Biol Phys. Dec 1; 2005 63(5):1568–75. [PubMed: 15990246]
16. Thomas O, Mahe M, Campion L, Bourdin S, Milpied N, Brunet G, et al. Long-term complications of total body irradiation in adults. Int J Radiat Oncol Biol Phys. Jan 1; 2001 49(1):125–31. [PubMed: 11163505]

17. Fahnehjelm KT, Tornquist AL, Olsson M, Winiarski J. Visual outcome and cataract development after allogeneic stem-cell transplantation in children. Acta Ophthalmol Scand. Nov; 2007 85(7):724–33. [PubMed: 17725615]

18. Kal HB, VANK-H ML. Induction of severe cataract and late renal dysfunction following total body irradiation: dose-effect relationships. Anticancer Res. Aug; 2009 29(8):3305–9. [PubMed: 19661349]

19. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB, et al. Solid cancers after bone marrow transplantation. N Engl J Med. Mar 27; 1997 336(13):897–904. [PubMed: 9070469]

20. Baker KS, Ness KK, Steinberger J, Carter A, Francisco L, Burns LJ, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood. Feb 15; 2007 109(4):1765–72. [PubMed: 17047152]

21. Taskinen M, Saarinen-Pihkala UM, Hovi L, Lipsanen-Nyman M. Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet Sep 16; 2000 356(9234):993–7. [PubMed: 11041401]

22. Leake E, Smith WG. Diffuse Interstitial Pulmonary Fibrosis after Busulphan Therapy. Lancet. Aug 31; 1963 2(7305):432–4. [PubMed: 14047274]

23. Kasai M, Kiyama Y, Watanabe M, Seto K, Matsuura A, Tanaka J, et al. Toxicity of high-dose busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation. Transplant Proc. Aug; 1992 24(4):1529–30. [PubMed: 1496647]

24. Wingard JR, Mellits ED, Sostrin MB, Chen DY, Burns WH, Santos GW, et al. Interstitial pneumonitis after allogeneic bone marrow transplantation. Nine-year experience at a single institution. Medicine (Baltimore). May 1988 67(3):175–86. [PubMed: 2835573]

25. Fraser CJ, Bhatia S, Ness K, Carter A, Francisco L, Arora M, et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood. Oct 15; 2006 108(8):2867–73. [PubMed: 16788100]
### Table 1
Clinical and demographic characteristics of the study population

|                      | Institution | Sex | Race/ethnicity | Transplant type | Stem cell source | Conditioning regimen |
|----------------------|-------------|-----|----------------|-----------------|------------------|---------------------|
|                      |             |     |                |                 |                  |                     |
|                      |             |     | White          | Related sibling | BM               | Chemotherapy         |
|                     |             |     | Black          | Autologous      | PBSC             | Chemotherapy & Radiation |
|                     |             |     | Native American| Unrelated       | BM & PBSC        |                     |
|                     |             |     | Asian          | Matched related | Cord Blood       |                     |
|                     |             |     | Hispanic       | Syngeneic       |                  |                     |
|                     |             |     | Other          |                 |                  |                     |

|                      | City of Hope | University of Minnesota | | | |
|----------------------|-------------|-------------------------| | | |
| Institution          | N=319       | N=281                   | N=120 | N=401 | N=319 |
|                      | N          | %                       | N     | %     | N   |
| Institution          | N          | %                       | N     | %     | p-value* |
| City of Hope         | 115        | (36.1)                  | 149   | (53.0)| 0.061 |
| University of Minnesota | 204   | (63.9)                  | 132   | (47.0)| <0.001 |
| Sex                  | 0.003      |                         | <0.001|       | <0.001 |
| Female               | 203        | (63.6)                  | 145   | (51.6)|       |
| Male                 | 116        | (36.4)                  | 136   | (48.4)|       |
| Race/ethnicity       | <0.001     |                         | <0.001| <0.001|       |
| White                | 296        | (92.8)                  | 230   | (81.9)|       |
| Black                | 4          | (1.3)                   | 1     | (0.4) |       |
| Native American      | 2          | (0.6)                   | 1     | (0.4) |       |
| Asian                | 3          | (0.9)                   | 16    | (5.7) |       |
| Hispanic             | 10         | (3.1)                   | 33    | (11.7)|       |
| Other                | 3          | (0.9)                   | 0     | (0.0) |       |
| Transplant type      |            |                         |       |       |       |
| Related sibling      | NA         | 157 (55.9)              | 82    | (68.3) |       |
| Autologous           | NA         | 93 (33.1)               | 20    | (16.7) |       |
| Unrelated            | NA         | 29 (10.3)               | 17    | (14.2) |       |
| Matched related      | NA         | 2 (0.7)                 | 0     | (0.0)  |       |
| Syngeneic            | NA         | 0 (0.0)                 | 1     | (0.8)  |       |
| Stem cell source     |            |                         |       |       |       |
| BM                   | NA         | 220 (78.3)              | 114   | (95.0) |       |
| PBSC                 | NA         | 43 (15.3)               | 3     | (2.5)  |       |
| BM & PBSC            | NA         | 14 (5.0)                | 1     | (0.8)  |       |
| Conditioning regimen |            |                         |       |       |       |
| Chemotherapy         | 40         | (14.2)                  | 0     | (0.0)  |       |
| Chemotherapy & Radiation | 241   | (85.8)                  | 120   | (100.0)|       |

*Significant p-values are indicated in bold.
|                  | Siblings (N=319) | AML (N=281) | ALL (N=120) | AML & ALL (401) |
|------------------|------------------|-------------|-------------|-----------------|
|                  | N    | %    | N    | %    | N    | %    | N    | %    |
| Chronic graft versus host disease † |      |      |      |      |      |      |      |      |
| Yes              | 88   | 46.8 | 39   | 39.4 | 127  | 44.3 |      |      |
| No               | 100  | 53.2 | 81   | 81.8 | 181  | 63.1 |      |      |

* Chi-square statistics, p-values represents a comparison between the HCT survivor group represented at the top of the column and the sibling comparison group.

† Limited to allogeneic transplants. BM=bone marrow, PBSC=peripheral blood stem cells.
Table 2

Prevalence of organ system impairments among survivors, overall and by diagnosis, compared to a sibling group

|                        | Siblings (N=319) | AML (N=281) | ALL (N=120) | AML & ALL (401) |
|------------------------|------------------|-------------|-------------|-----------------|
|                        | N %              | N %         | p-value*    | N %             | p-value*    | N %         | p-value*    | N %             | p-value*    |
| **Eye impairments**    |                  |             |             |                 |             |             |             |                 |             |
| Eye impairments        | 36 (11.3)        | 118 (42.0)  | <0.001      | 61 (50.8)       | <0.001      | 179 (44.6)  | <0.001      | 244 (40.9)     | <0.001      |
| Cataracts              | 12 (3.8)         | 94 (33.5)   | <0.001      | 52 (43.3)       | <0.001      | 146 (36.4)  | <0.001      | 198 (30.0)     | <0.001      |
| Glaucoma               | 6 (1.9)          | 5 (1.8)     | 0.99        | 2 (1.7)         | 0.79        | 7 (1.7)     | 0.94        |                  |             |
| Dry eyes               | 26 (8.2)         | 47 (16.7)   | <0.001      | 17 (14.2)       | <0.001      | 64 (16.0)   | <0.001      |                  |             |
| **Oral health impairments** |            |             |             |                 |             |             |             |                 |             |
| Oral health impairments| 41 (12.9)        | 65 (23.1)   | 0.001       | 25 (20.8)       | 0.07        | 90 (22.4)   | 0.002       |                  |             |
| Dry mouth              | 3 (0.9)          | 31 (11.0)   | <0.001      | 12 (10.0)       | <0.001      | 43 (10.7)   | <0.001      |                  |             |
| Swollen or bleeding gums | 35 (11.0)     | 27 (9.6)    | 0.59        | 15 (12.5)       | 0.81        | 42 (10.5)   | 0.63        |                  |             |
| Problems chewing or swallowing | 4 (1.3) | 25 (8.9) | <0.001 | 6 (5.0) | 0.11 | 31 (7.7) | <0.001 | |
| **Endocrine impairments** |             |             |             |                 |             |             |             |                 |             |
| Hypothyroid            | 23 (7.2)         | 61 (21.7)   | <0.001      | 32 (26.7)       | <0.001      | 93 (23.2)   | <0.001      |                  |             |
| Diabetes               | 10 (3.1)         | 27 (9.6)    | <0.001      | 9 (7.5)         | 0.04        | 36 (9.0)    | <0.001      |                  |             |
| Hyperthyroid           | 5 (1.6)          | 7 (2.5)     | 0.47        | 0 (0.0)         | 0.95        | 7 (1.7)     | 0.79        |                  |             |
| Thyroid nodules        | 8 (2.5)          | 1 (0.4)     | 0.12        | 3 (2.5)         | 0.23        | 4 (1.0)     | 0.31        |                  |             |
| **Bone impairments**   | 8 (2.5)          | 41 (14.6)   | <0.001      | 12 (10.0)       | <0.001      | 53 (13.2)   | <0.001      |                  |             |
| Bone impairments       | 8 (2.5)          | 41 (14.6)   | <0.001      | 12 (10.0)       | <0.001      | 53 (13.2)   | <0.001      |                  |             |
| Osteoporosis           | 7 (2.2)          | 25 (8.9)    | <0.001      | 11 (9.2)        | <0.001      | 36 (9.0)    | <0.001      |                  |             |
| Avascular necrosis     | 1 (0.3)          | 20 (7.1)    | 0.001       | 3 (2.5)         | 0.02        | 23 (5.7)    | 0.002       |                  |             |
| **Cardiopulmonary impairments** |             |             |             |                 |             |             |             |                 |             |
| Cardiopulmonary impairments | 83 (26.0) | 82 (29.2) | 0.1 | 36 (30.0) | 0.08 | 118 (29.4) | 0.1 | |
| Arrhythmia             | 17 (5.3)         | 13 (4.6)    | 0.81        | 5 (4.2)         | 0.73        | 18 (4.5)    | 0.86        |                  |             |
| Congestive heart failure | 1 (0.3)         | 7 (2.5)     | 0.06        | 1 (0.8)         | 0.41        | 8 (2.0)     | 0.09        |                  |             |
| Myocardial infarction  | 5 (1.6)          | 4 (1.4)     | 0.88        | 0 (0.0)         | 0.96        | 4 (1.0)     | 0.87        |                  |             |
| Coronary heart disease | 5 (1.6)          | 3 (1.1)     | 0.76        | 0 (0.0)         | 0.95        | 3 (0.7)     | 0.56        |                  |             |
| Hypertension           | 61 (19.1)        | 52 (18.5)   | 0.69        | 17 (14.2)       | 0.88        | 69 (17.2)   | 0.91        |                  |             |
| Stroke                 | 1 (0.3)          | 4 (1.4)     | 0.16        | 4 (3.3)         | 0.03        | 8 (2.0)     | 0.1         |                  |             |
| Angina                 | 3 (0.9)          | 2 (0.7)     | 0.98        | 0 (0.0)         | 0.96        | 2 (0.5)     | 0.82        |                  |             |
| Exercise induced shortness of breath | 8 (2.5) | 17 (6.0) | 0.02 | 16 (13.3) | <0.001 | 33 (8.2) | 0.004 | |
| Pericarditis           | 0 (0.0)          | 10 (3.6)    | 0.94        | 1 (0.8)         | 0.96        | 11 (2.7)    | 0.94        |                  |             |
| Stiff or leaking heart valves | 7 (2.2) | 4 (1.4) | 0.75 | 2 (1.7) | 0.45 | 6 (1.5) | 0.84 | |
| Condition                        | Siblings (N=319) | ALL (N=281) | AML (N=120) | AML & ALL (401) |
|---------------------------------|------------------|-------------|-------------|-----------------|
| Blood clot in extremities       | 4 (1.3)          | 12 (4.3)    | 0.04 3 (2.5) | 0.65 15 (3.7)   |
| Lung fibrosis                   | 0 (0.0)          | NE          | NE          | NE              |
| Gastrointestinal impairments    | 29 (9.1)         | 45 (16.0)   | 0.004 19 (15.8) | 0.001 64 (16.0) |
| Gall stones                     | 0 (0.0)          | 23 (8.2)    | 0.04 8 (6.7)  | 0.01 31 (7.7)   |
| Cirrhosis of liver              | 0 (0.0)          | 2 (0.7)     | 0.04 2 (1.7)  | 0.04 3 (0.7)    |
| Hepatitis                       | 6 (1.9)          | 15 (5.3)    | 0.003 10 (8.3) | 0.004 25 (6.2)  |
| Esophageal stricture or scarring| 0 (0.0)          | 12 (4.3)    | 0.04 11 (9.2) | 0.08 12 (3.0)   |
| Blind                           | 5 (1.6)          | 8 (2.8)     | 0.2 3 (2.5)   | 0.07 11 (2.7)   |
| Tingling or ringing in ears     | 2 (0.6)          | 10 (3.6)    | 0.37 0 (0.0)  | 0.96 10 (2.5)   |
| Complete or partial deafness    | 0 (0.0)          | 9 (3.2)     | 0.02 6 (5.0)  | 0.02 13 (3.2)   |
| Abnormal sense of taste or smell| 2 (0.6)          | 3 (1.1)     | <0.001 28 (23.3) | 0.01 112 (27.9) |
| Abnormal sense of touch         | 4 (1.3)          | 17 (6.0)    | 0.09 5 (4.2)  | 0.09 23 (5.7)   |
| Dizziness or vertigo            | 10 (3.1)         | 17 (6.0)    | 0.001 14 (11.7) | 0.001 42 (10.5) |
| Abnormal cerebral reflex        | 0 (0.0)          | 7 (2.5)     | 0.02 6 (5.0)  | 0.02 13 (3.2)   |
| Neuronomotor impairments        | 20 (6.3)         | 45 (16.0)   | 0.004 19 (15.8) | 0.001 64 (16.0) |
| Paralysis                       | 3 (0.9)          | 5 (1.8)     | 0.28 1 (0.8)  | 0.08 6 (1.5)    |
| Balance, tremor or weakness     | 17 (5.3)         | 44 (15.3)   | 0.001 10 (8.3) | 0.003 34 (5.5)  |
| Neurological impairments        | 78 (24.5)        | 43 (15.3)   | 0.02 24 (20.0) | 0.05 67 (16.7)  |
| Seizures or epilepsy            | 8 (2.5)          | 9 (3.2)     | 0.06 6 (5.0)  | 0.18 15 (3.7)   |
| Headaches or migraines          | 73 (22.9)        | 37 (12.2)   | 0.012 21 (17.5) | 0.08 38 (9.5)   |
| Recurrence or second cancer     | 5 (1.6)          | 17 (6.0)    | 0.004 13 (10.8) | <0.001 30 (7.5) |

* p-values are generated from generalized estimating equations adjusted for age and gender and including variance component for intra-family correlation. Fisher’s exact test used for cell sizes smaller than 5. Each p-value represents a comparison between the HCT survivor group represented at the top of the column and the sibling comparison group. NE=not estimated.
|                        | Siblings (N=319) | AML (N=281) | ALL (N=120) | AML & ALL (401) |
|------------------------|-----------------|-------------|-------------|-----------------|
|                        | N   | %   | N   | %   | p-value* | N   | %   | p-value* | N   | %   | p-value* |
| Assistance with daily  |     |     |     |     |          |     |     |          |     |     |          |
| living                 |     |     |     |     |          |     |     |          |     |     |          |
| Yes                    | 1   | (0.3) | 9   | (3.2) | 3     | (2.5) | 12   | (3.0)   | 0.007 | 0.08 | 0.01    |
| No                     | 318 | (99.7) | 272 | (96.8) | 117   | (97.5) | 389  | (97.0)   |        |      |         |
| Assistance with routine|     |     |     |     |          |     |     |          |     |     |          |
| activities             |     |     |     |     |          |     |     |          |     |     |          |
| Yes                    | 8   | (2.5) | 23  | (8.2) | 8     | (6.7) | 31   | (7.7)   | 0.005 | 0.03 | 0.004   |
| No                     | 311 | (97.5) | 258 | (91.8) | 112   | (93.3) | 370  | (92.3)   |        |      |         |
| Health prevents work   |     |     |     |     |          |     |     |          |     |     |          |
| or school attendance   |     |     |     |     |          |     |     |          |     |     |          |
| Yes                    | 7   | (2.2) | 40  | (14.2) | 15    | (12.5) | 55   | (13.7)  | <0.001 | <0.001 | <0.001  |
| No                     | 312 | (97.8) | 241 | (85.8) | 104   | (87.5) | 345  | (86.3)   |        |      |         |
| General health         |     |     |     |     |          |     |     |          |     |     |          |
| Poor                   | 0   | (0.0) | 11  | (3.9) | 4     | (3.3) | 15   | (3.7)   | <0.001 | <0.001 | <0.001  |
| Fair                   | 17  | (5.3) | 38  | (13.5) | 14    | (11.7) | 52   | (13.0)  |        |      |         |
| Good                   | 66  | (20.7) | 103 | (36.7) | 40    | (33.3) | 143  | (35.7)  |        |      |         |
| Very good              | 156 | (48.9) | 79  | (28.1) | 46    | (38.3) | 125  | (31.2)  |        |      |         |
| Excellent              | 80  | (25.1) | 49  | (17.4) | 15    | (12.5) | 64   | (16.0)  |        |      |         |

Fisher's exact test used for cell sizes smaller than 5.

*p-values are generated from generalized estimating equations adjusted for age and gender an including variance component for intrafamily correlation.
Predictors of a medical late effects among HCT survivors

| All HCT Survivors | Cataracts | OR | 95% CI | p-value | Dry eyes | OR | 95% CI | p-value | Dry mouth | OR | 95% CI | p-value | Hypothyroidism | OR | 95% CI | p-value |
|-------------------|-----------|----|--------|---------|----------|----|--------|---------|-----------|----|--------|---------|----------------|----|--------|---------|
| Diagnosis         |           |    |        |         |          |    |        |         |            |    |        |         |                |    |        |         |
| AML               | referent  |    |        |         |          |    |        |         | referent   |    |        |         | referent       |    |        |         |
| ALL               | 0.86      | 0.5–1.5 | 0.6   | 0.76     | 0.4–1.5 | 0.4 | 0.97   | 0.4–2.1 | 0.94       | 1.07 | 0.6–1.9 | 0.8    |               |    |        |         |
| Transplant type   |           |    |        |         |          |    |        |         |            |    |        |         |                |    |        |         |
| Autologous        | referent  |    |        |         | referent |    |        |         | referent   |    |        |         | referent       |    |        |         |
| Allogeneic        | 1.36      | 0.8–2.3 | 3.79  | 1.7–8.6 | 0.001   | 1.24 | 0.6–2.6 | 0.6     | 0.60       | 0.3–1.1 | 0.09   |        |        |         |         |
| Conditioning regimen |         |    |        |         |            |    |        |         |            |    |        |         |                |    |        |         |
| Chemotherapy only | referent  |    |        |         | referent |    |        |         | referent   |    |        |         | referent       |    |        |         |
| Radiation & chemo | 4.58      | 1.6–12.8 | 2.29  | 0.7–8.1 | 0.2     | 0.94   | 0.3–3.0 | 0.9     | 1.76       | 0.6–5.7 | 0.3    |        |        |         |         |
| Sex               |           |    |        |         |          |    |        |         |            |    |        |         |                |    |        |         |
| Male              | referent  |    |        |         | referent |    |        |         | referent   |    |        |         | referent       |    |        |         |
| Female            | 0.95      | 0.6–1.5 | 0.8   | 1.23     | 0.7–2.1 | 0.5 | 0.51   | 0.3–1.0 | 0.06       | 1.65 | 0.97–2.8 | 0.06  |        |        |         |
| All HCT Survivors | Diabetes  | OR | 95% CI | p-value | Osteoporosis | OR | 95% CI | p-value | Avascular necrosis | OR | 95% CI | p-value | Exercise induced shortness of breath | OR | 95% CI | p-value |
| Diagnosis         |           |    |        |         |          |    |        |         |            |    |        |         |                |    |        |         |
| AML               | referent  |    |        |         |          |    |        |         | referent   |    |        |         | referent       |    |        |         |
| ALL               | 0.54      | 0.2–1.3 | 0.2   | 1.01     | 0.4–2.3 | 0.98 | 0.27   | 0.1–1.0 | 0.06       | 2.03 | 0.9–4.6 | 0.09  |               |    |        |         |
| Transplant type   |           |    |        |         |          |    |        |         |            |    |        |         |                |    |        |         |
| Autologous        | referent  |    |        |         | referent |    |        |         | referent   |    |        |         | referent       |    |        |         |
| Allogeneic        | 3.92      | 1.1–14.0 | 0.04  | 3.10     | 1.0–9.4 | 0.05 | 5.38   | 1.2–25.0 | 0.03      | 1.03 | 0.4–2.7 | 0.9   |               |    |        |         |
| Conditioning regimen |         |    |        |         |            |    |        |         |            |    |        |         |                |    |        |         |
| Chemotherapy only | referent  |    |        |         | referent |    |        |         | referent   |    |        |         | referent       |    |        |         |
| Radiation & chemo | 1.0       | 2.51  | 0.3–20.5 | 0.4   | 1.81     | 0.2–14.8 | 0.6 | 0.66   | 0.1–3.3 | 0.6    |        |        |         |         |
| Sex               |           |    |        |         |          |    |        |         |            |    |        |         |                |    |        |         |
| Male              | referent  |    |        |         | referent |    |        |         | referent   |    |        |         | referent       |    |        |         |
| Female            | 0.86      | 0.4–1.9 | 0.7   | 3.25     | 1.4–7.4 | 0.005 | 0.64   | 0.3–1.6 | 0.3      | 0.43 | 0.2–1.1 | 0.07  |        |        |         |
Table 5

Predictors of a medical late effects among allogeneic HCT recipients

| All HCT Survivors | Cataracts | Dry eyes | Dry mouth | Hypothyroidism |
|-------------------|-----------|----------|-----------|----------------|
| Diagnosis         | OR        | 95% CI   | p-value   | OR             | 95% CI | p-value | OR     | 95% CI | p-value |
| AML               | referent  | referent | referent  | referent       |        |         |        |        |         |
| ALL               | 0.76      | 0.4–1.3  | 0.3       | 0.89           | 0.4–1.8| 0.7     | 1.11   | 0.5–2.7| 0.8     | 1.08   | 0.6–2.0| 0.8    |
| Conditioning regimen |         |          |           |                |        |         |        |        |         |
| Chemotherapy only | referent  | referent | referent  | referent       |        |         |        |        |         |
| Radiation & chemo | 5.33      | 1.4–19.7 | 0.01      | 1.50           | 0.4–5.7| 0.6     | 0.59   | 0.2–2.3| 0.5     | 0.96   | 0.2–4.8| 1.0    |
| Chronic graft versus host disease |         |          |           |                |        |         |        |        |         |
| No                | referent  | referent | referent  | referent       |        |         |        |        |         |
| Yes               | 0.82      | 0.5–1.4  | 0.5       | 3.26           | 1.7–5.4| <0.001 | 2.36   | 1.0–5.4| 0.04    | 1.26   | 0.6–2.6| 0.5    |
| Sex               |           |          |           |                |        |         |        |        |         |
| Male              | referent  | referent | referent  | referent       |        |         |        |        |         |
| Female            | 1.00      | 0.6–1.7  | 1.0       | 1.69           | 0.9–3.1| 0.09    | 0.99   | 0.5–2.2| 1.0     | 1.39   | 0.7–2.6| 0.3    |

|                  | Diabetes | Osteoporosis | Avascular necrosis | Exercise induced shortness of breath |
|-------------------|----------|--------------|--------------------|--------------------------------------|
| Diagnosis         | OR       | 95% CI       | p-value            | OR                                   | 95% CI | p-value | OR             | 95% CI | p-value | OR             | 95% CI | p-value |
| AML               | referent | referent     | referent           | referent                             |        |         | referent       |        |         | referent       |        |         |
| ALL               | 0.45     | 0.2–1.2      | 0.1                | 1.16                                 | 0.5–2.7| 0.7     | 0.31           | 0.1–1.2| 0.08    | 2.10           | 0.8–5.2| 0.1     |
| Conditioning regimen |         |              |                    |                                       |        |         | referent       |        |         | referent       |        |         |
| Chemotherapy only | NE       | referent     | referent           | referent                             |        |         | referent       |        |         | referent       |        |         |
| Radiation & chemo | 1.76     | 0.2–15.2     | 0.6                | 1.14                                 | 0.1–9.9| 0.9     | 0.17           | 0.03–1.0| 0.05   | 3.40           | 1.1–10.2| 0.03   |
| Chronic graft versus host disease |         |              |                    |                                       |        |         | referent       |        |         | referent       |        |         |
| No                | referent | referent     | referent           | referent                             |        |         | referent       |        |         | referent       |        |         |
| Yes               | 1.82     | 0.7–4.5      | 0.2                | 1.06                                 | 0.4–2.6| 0.9     | 2.18           | 0.8–6.1| 0.1    | 3.40           | 1.1–10.2| 0.03   |
| Sex               |           |              |                    |                                       |        |         | referent       |        |         | referent       |        |         |
| Male              | referent | referent     | referent           | referent                             |        |         | referent       |        |         | referent       |        |         |
| Female            | 1.16     | 0.5–2.6      | 0.7                | 3.30                                 | 1.4–8.0| 0.008  | 0.67           | 0.3–1.7| 0.4    | 0.72           | 0.3–2.0| 0.5    |
Table 6

Predictors activity limitations among HCT recipients.

|                        | Abnormal sense of touch | Balance problems, tremor or weakness | Health prevents school or work attendance | Self-reported poor or fair health |
|------------------------|-------------------------|--------------------------------------|------------------------------------------|----------------------------------|
|                        | OR  | 95% CI   | p-value | OR  | 95% CI | p-value | OR  | 95% CI | p-value | OR  | 95% CI | p-value |
| All HCT Recipients     |     |          |         |     |        |         |     |        |         |     |        |         |
| Diagnosis              |     |          |         |     |        |         |     |        |         |     |        |         |
| AML                   | referent |        |         | referent |        |         | referent |        |         | referent | referent |         |         |
| ALL                   | 0.58 | 0.3–1.2 | 0.1 | 0.55 | 0.3–1.2 | 0.1 | 1.29 | 0.6–2.6 | 0.5 | 0.93 | 0.5–1.8 | 0.8 |
| Transplant type        |     |          |         |     |        |         |     |        |         |     |        |         |
| Autologous            | referent |        |         | referent |        |         | referent |        |         | referent |         |         |         |
| Allogeneic            | referent |        |         | referent |        |         | referent |        |         | referent |         |         |         |
| Conditioning regimen  |     |          |         |     |        |         |     |        |         |     |        |         |
| Chemotherapy only     | referent |        |         | referent |        |         | referent |        |         | referent |         |         |         |
| Radiation & chemo     | 1.42 | 0.4–5.1 | 0.6 | 5.38 | 0.7–41.8 | 0.1 | 1.2 | 0.3–4.4 | 0.8 | 1.15 | 0.4–3.6 | 0.8 |
| Sex                   |     |          |         |     |        |         |     |        |         |     |        |         |
| Male                  | referent |        |         | referent |        |         | referent |        |         | referent |         |         |         |
| Female                | 1.18 | 0.7–2.1 | 0.6 | 2.43 | 1.3–4.7 | 0.008 | 1.57 | 0.9–2.9 | 0.2 | 0.81 | 0.5–1.4 | 0.5 |
| Allogeneic Recipients |     |          |         |     |        |         |     |        |         |     |        |         |
| Diagnosis              |     |          |         |     |        |         |     |        |         |     |        |         |
| AML                   | referent |        |         | referent |        |         | referent |        |         | referent | referent |         |         |
| ALL                   | 0.57 | 0.3–1.2 | 0.1 | 0.65 | 0.3–1.5 | 0.3 | 1.47 | 0.7–3.2 | 0.3 | 1.05 | 0.5–2.1 | 0.9 |
| Conditioning regimen  |     |          |         |     |        |         |     |        |         |     |        |         |
| Chemotherapy only     | referent |        |         | NE | referent |        | referent |        |         | referent |         |         |         |
| Radiation & chemo     | 0.72 | 0.2–2.9 | 0.6 | 0.47 | 0.1–2.0 | 0.3 | 1.49 | 0.3–7.6 | 0.6 |
| Chronic graft versus host disease |     |          |         |     |        |         |     |        |         |     |        |         |
| No                    | referent |        |         | referent |        |         | referent |        |         | referent | referent |         |         |
| Yes                   | 2.26 | 1.2–4.7 | 0.03 | 2.64 | 1.1–6.1 | 0.02 | 2.93 | 1.3–6.4 | 0.008 | 1.3 | 0.7–2.6 | 0.5 |
| Sex                   |     |          |         |     |        |         |     |        |         |     |        |         |
| Male                  | referent |        |         | referent |        |         | referent |        |         | referent |         |         |         |
| Female                | 1.42 | 0.7–2.8 | 0.30 | 3.73 | 1.7–8.4 | 0.002 | 1.61 | 0.8–3.3 | 0.2 | 0.68 | 0.4–1.3 | 0.3 |

*Adjusted for age at interview and age at transplant